Earnings Routine −

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

Pre-revenue biotech burns through cash, relies on distant government milestones while facing immediate going-concern liquidity crunch.

By The Northwire Desk — AI Analysis Jun 26, 2026 · 18:29 APLI · 0.015 APPILI THERAPEUTICS INC. J

Executive Summary

Appili Therapeutics reported FYE 2026 financial results showing a net loss of $4.2 million ($0.03/share), an increase from $2.6 million in the prior year.
Cash on hand plummeted to $0.04 million as of March 31, 2026, down from $1.2 million a year earlier, triggering a going concern note due to reliance on future equity and non-dilutive funding.
The company secured a US$40 million NIAID contract for the VXV-01 antifungal vaccine, though only a $3.6 million base period is available initially, with options extending to Phase 1.
Additional US$14 million in USAFA funding was secured for the ATI-1701 tularemia vaccine candidate.
Commercial momentum is noted for LIKMEZ (ATI-1501) in the U.S., generating royalties and milestones.
Regulatory progress includes FDA alignment on a bridging strategy for ATI-1801 and successful GMP manufacturing for ATI-1701.
Lender extensions on the LZH and Bloom Burton Loans were secured to June/July 2026, contingent on completing an equity financing of at least CAD $350,000 by June 30, 2026.
Capitalization stands at 132.3 million common shares, 11.9 million stock options, and 41.4 million warrants.

Material Impact

The most recent release confirms a severe liquidity deterioration, with cash reserves effectively exhausted ($0.04M) and a formal going concern warning.
While the US$40M NIAID contract and US$14M USAFA funding are strategically significant, they are multi-year, milestone-based, and non-dilutive, meaning they do not provide immediate working capital to cover current burn rates.
The contingent requirement to raise CAD $350,000 by June 30, 2026, to avoid loan default underscores an immediate capital need that will likely result in significant equity dilution at the current $0.01 share price.
The market has already priced in the government contract news from October 2025 (when the stock briefly spiked to $0.04), and the current earnings release merely confirms the execution of that strategy alongside worsening cash positions.
The news is not a fundamental re-rating event; it is a confirmation of the company's ongoing cash burn and dependence on future financing, which is typical for pre-revenue biotechs but remains highly risky.

APLI · Price

Company Overview

Appili Therapeutics is a clinical-stage biotechnology company focused on infectious diseases and biodefense.
Core initiatives include the development of the VXV-01 antifungal vaccine (NIAID-funded), ATI-1701 tularemia vaccine (USAFA-funded), and ATI-1801 topical antiparasitic for leishmaniasis.
The company also commercializes LIKMEZ (ATI-1501), a liquid metronidazole product, through a partnership with Saptalis in the U.S. market.
The business model heavily relies on non-dilutive government funding and strategic partnerships to advance its pipeline while minimizing equity dilution.

More from APPILI THERAPEUTICS INC. J